Dr. Chari on Quadruplet Regimens in Transplant-Eligible Multiple Myeloma

Video

In Partnership With:

Ajai Chari, MD, discusses the implementing quadruplet-regimens in transplant-eligible multiple myeloma.

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses implementing quadruplet regimens in transplant-eligible multiple myeloma.

The phase III CASSIOPEIA trial demonstrated an improved progression-free survival (PFS) at a median follow-up of 18.8 months, as well as deep responses, with the addition of daratumumab (Darzalex) to bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd) in newly diagnosed patients. As such, the FDA approved daratumumab plus VTd in September 2019.

Similarly, the phase I/II GRIFFIN study suggested that quadruplet therapy with daratumumab plus lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) may improve depth of the response compared with RVd alone; however, survival data are pending, explains Chari.

Following frontline quadruplet therapy and autologous stem cell transplant, maintenance therapy with lenalidomide is suggested, concludes Chari.

Lenalidomide in combination with daratumumab as maintenance therapy will be explored in an upcoming phase III clinical trial called AURIGA (NCT03901963) to potentially extend remission duration for this patient population who have minimal residual disease positivity after transplant.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute